Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Condition: Refractory Solid Tumors Interventions: Drug: Eribulin; Drug: Irinotecan; Drug: Temozolomide Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Condition: Refractory Solid Tumors Interventions: Drug: Eribulin; Drug: Irinotecan; Drug: Temozolomide Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Condition: Refractory Solid Tumors Interventions: Drug: Eribulin; Drug: Irinotecan; Drug: Temozolomide Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Condition: Refractory Solid Tumors Interventions: Drug: Eribulin; Drug: Irinotecan; Drug: Temozolomide; Drug: Cefpodoxime; Drug: Cefixime Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Conditions: Neoplasms; Child; Adolescent Interventions: Drug: Ramucirumab; Drug: Cyclophosphamide; Drug: Vinorelbine; Drug: Gemcitabine; Drug: Docetaxel; Drug: Abemaciclib; Drug: Irinotecan; Drug: Temozolomide Sponsor: Eli Lilly and Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 21, 2023 Category: Research Source Type: clinical trials